Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar

Tropical Medicine and International Health

Volumn 13, Issue 9, 2008, Pages 1208-1212

  Sundar, S ^a   Chakravarty, J ^a   Agarwal, D ^a   Shah, A ^a   Agrawal, N ^a   Rai, M ^a  

^a NONE

Author keywords

Amphotericin B; Fat emulsion; India; Kala azar

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; PARACETAMOL; PHENIRAMINE;

ANTIBIOTIC RESISTANCE; DISEASE TREATMENT; DOSE-RESPONSE RELATIONSHIP; EMULSION; LEISHMANIASIS; LIPID; SAFETY; TOXICITY TEST;

ADOLESCENT; ADULT; ARTICLE; ASPIRATION; BODY TEMPERATURE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INDIA; INJECTION SITE REACTION; LEISHMANIASIS; MALE; NEPHROTOXICITY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHILD; DEOXYCHOLIC ACID; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FAT EMULSIONS, INTRAVENOUS; FEMALE; HUMANS; INDIA; INFUSIONS, INTRAVENOUS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ASIA; BIHAR; EURASIA; INDIA; SOUTH ASIA;

NASO HEXACANTHUS;

EID: 50049110427     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2008.02128.x     Document Type: Article

References (17)

1. Barquist E, Fein E, Shadick D, Johnson J, Clark J Shatz D (1999) A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients. Journal of Trauma 47, 336 340.
2. Chulay JD Bryceson AD (1983) Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. The American Journal of Tropical Medicine and Hygiene 32, 475 479.
3. Hernandez G, Altermatt F, Bernucci F et al. (2000) Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients? Revista Medica de Chile 128, 1101 1107.
4. Maserati PP, Viale GE, Rivolta P, Villians F, Alberici M Regazzi B (1993) Amphotericin B (Am-B) in lipid emulsion for the treatment of mycoses in AIDS. International Conference on AIDS 9, 362.
5. Mishra M, Biswas UK, Jha DN Khan AB (1992) Amphotericin versus pentamidine in antimony unresponsive Kala-azar. Lancet 340, 1256 1257.
6. Nucci M, Loureiro M, Silveira F et al. (1999) Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrobial Agents and Chemotherapy 43, 1445 1448.
7. Sorkine P, Nagar H, Weinboum A et al. (1997) Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: a controlled study in critically ill patients. Critical Care 1, 640.
8. Sundar S Murray HW (2005) Availability of miltefosine for the treatment of Kala-azar in India. Bulletin of World Health Organization 83, 394 395.
9. Sundar S Rai M (2005) Treatment of visceral leishmaniasis. Expert Opinion on Pharmacotherapy 6, 2821 2829.
10. Sundar S, Singh VP, Sharma S, Makharia MK Murray HW (1997) Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. Journal of Infectious Diseases 176, 1117 1119.
11. Sundar S, Gupta LB, Rastogi V, Agrawal G Murray HW (2000a) Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Transactions of Royal Society of Tropical Medicine and Hygiene 94, 200 204.
12. Sundar S, More DK, Singh MK et al. (2000b) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clinical Infectious Diseases 31, 1104 1107.
13. Sundar S, Agrawal G, Rai M, Makharia MK Murray HW (2001) Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323, 419 422.
14. Sundar S, Jha TK, Thakur CP et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine 347, 1739 1746.
15. Sundar S, Jha TK, Thakur CP, Sinha PK Bhattacharya SK (2007) Injectable paromomycin for visceral leishmaniasis in India. New England Journal of Medicine 356, 2571 2581.
16. Thakur CP Narayan S (2004) A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Annals of Tropical Medicine and Parasitology 98, 129 138.
17. Thakur CP, Sinha GP, Sharma V, Pandey AK, Kumar M Verma BB (1993) Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of Kala-azar. Indian Journal of Medical Research 97, 170 175.